trial

Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

NCTId NCT03860597
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 42 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2021-03-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
42 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2018-04-01
Primary completion
2021-03-31
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Memantine

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Sites

1 total
San Diego, United States

Facts & assertions

4 sourced
Enrollment
42
Phase
PHASE4
Primary Completion Date
2021-03-31
Status
COMPLETED
relationships
The graph out of here
drug
Memantine
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizo Affective Disorder
indication
Schizoaffective Disorder
indication
Healthy
indication